aprocitentan
Trade name: TRYVIOTM
Small moleculeapproved
Approved
Mar 19, 2024
An era is a span of time defined for the purposes of chronology or historiography, as in the regnal eras in the history of a given monarchy, a calendar era used for a given calendar, or the geological eras defined for the history of Earth. — Wikipedia
Clinical trial activity
13 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
10
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jan 25, 2016 (NCT02603809)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2018
Idorsia Pharmaceuticals Ltd. — Earliest Phase 3 Sponsor(trial)
2020s
- Mar 19, 2024
Idorsia Pharmaceuticals Ltd. — Earliest FDA Approval
- Mar 19, 2024
Idorsia Pharmaceuticals Ltd. — NDA Organization
Indications
Approved for
Mechanism of action
- Endothelin receptor, ET-A/ET-BANTAGONIST
Endothelin receptor, ET-A/ET-B antagonist
- Endothelin-1INHIBITOR
inhibitor - edn1
Approval history
- approvedMar 19, 2024
Chemistry & pharmacology
Loading structure…
SMILES
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1- Mol. weight
- 546.2 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warningFirst in class
Sources
- WikipediaEra ↗
- ChEMBLCHEMBL2165326 ↗
Also known as
- act-132577
- act-132577
- era
- era
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06799884 | Phase 1 | Jan 18, 2025 | Idorsia Pharmaceuticals Ltd. |
| NCT05196399 | Phase 1 | Feb 2, 2022 | Idorsia Pharmaceuticals Ltd. |
| NCT04252495 | Phase 1 | Feb 29, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT04281342 | Phase 1 | Jan 14, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT04162366 | Phase 3 | Dec 11, 2019 | Idorsia Pharmaceuticals Ltd., Janssen Pharmaceutica NV |
| NCT03586570 | Phase 1 | Jul 17, 2018 | Idorsia Pharmaceuticals Ltd., Janssen Pharmaceutica NV |
| NCT03541174 | Phase 3 | Jun 18, 2018 | Idorsia Pharmaceuticals Ltd., Janssen Pharmaceutica NV |
| NCT03245229 | Phase 1 | Aug 10, 2017 | Idorsia Pharmaceuticals Ltd. |
| NCT03165071 | Phase 1 | Jun 3, 2017 | Actelion |
| NCT03100591 | Phase 1 | Mar 28, 2017 | Actelion |
| NCT02841761 | Phase 1 | Jul 1, 2016 | Actelion |
| NCT02708004 | Phase 1 | Jun 1, 2016 | Actelion |
| NCT02603809 | Phase 2 | Jan 25, 2016 | Actelion |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | 8 | 8 | 2 | 2017 |
| Actelion | For profit | 5 | 5 | 2 | 2016 |
| Janssen Pharmaceutica NV | For profit | 3 | 0 | 2 | 2018 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | NDA | Mar 19, 2024 |